USD 45.945
↓ -2.685 (-5.52%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| KYMR | -5.5 | -7.9 | 2.6 | 4.3 | 27.8 | 154.0 | -25.0 | 38.1 | 38.1 | 38.1 |
| S&P 500 | -0.6 | -0.5 | 2.3 | 7.3 | 12.1 | 32.1 | 27.0 | 90.7 | 191.4 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | KYMR |
| name | Kymera Therapeutics, Inc. |
| price | 45.95 |
| changes percentage | -5.52 |
| change | -2.69 |
| day low | 45.89 |
| day high | 49.09 |
| year high | 53.27 |
| year low | 16.95 |
| market cap | 2975641709 |
| price avg 50 | 47.26 |
| price avg 200 | 40.60 |
| exchange | NASDAQ |
| volume | 413639 |
| avg volume | 413215 |
| open | 48.70 |
| previous close | 48.63 |
| eps | -2.34 |
| pe | -19.63 |
| earnings announcement | 2025-02-20T12:00:00.000+0000 |
| shares outstanding | 64765300 |
| timestamp | 2024-11-14 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001815442 | |||
| revenue | 78592000 | 46826000 | 67.84 |
| gross profit | -110489000 | 43849000 | -351.98 |
| gross profit ratio | -1.41 | 0.94 | -250.13 |
| research and development expenses | 189081000 | 164248000 | 15.12 |
| operating expenses | 244122000 | 208082000 | 17.32 |
| interest income | 18764000 | 6624000 | 183.27 |
| interest expense | 196000 | 176000 | 11.36 |
| ebitda | -143201000 | -151655000 | 5.57 |
| ebitdaratio | -1.82 | -3.3 | 44.82 |
| operating income | -165530000 | -161256000 | -2.65 |
| operating income ratio | -2.11 | -3.44 | 38.84 |
| net income | -146962000 | -151831000 | 3.21 |
| net income ratio | -1.87 | -3.24 | 42.33 |
| eps | -2.52 | -2.82 | 10.64 |
Revenue Growth: revenue increased to 79 million in 2023 from 47 million in 2022 representing a change of 67.84%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 189 million in 2023 from 164 million in 2022 representing a change of 15.12%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Income: Operating income increased to -166 million in 2023 from -161 million in 2022 representing a change of -2.65%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -2.52 in 2023 from -2.52 in 2022 representing a change of 10.64%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to -110 million in 2023 from 44 million in 2022 representing a change of -351.98%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 244 million in 2023 from 208 million in 2022 representing a change of 17.32%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -143 million in 2023 from -152 million in 2022 representing a change of 5.57%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to -147 million in 2023 from -152 million in 2022 representing a change of 3.21%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001815442 | |||
| revenue | 3741000 | 25650000 | -85.42 |
| gross profit | 1741000 | 23750000 | -92.67 |
| gross profit ratio | 0.47 | 0.93 | -49.74 |
| research and development expenses | 60410000 | 57302000 | 5.42 |
| operating expenses | 75865000 | 74675000 | 1.59 |
| interest income | 9697000 | 8924000 | 8.66 |
| interest expense | 60000 | 61000 | -1.64 |
| ebitda | -60427000 | -40101000 | -50.69 |
| ebitdaratio | -16.15 | -1.91 | -745.11 |
| operating income | -72124000 | -50925000 | -41.63 |
| operating income ratio | -19.28 | -1.99 | -871.07 |
| net income | -62487000 | -42062000 | -48.56 |
| net income ratio | -16.7 | -1.64 | -918.59 |
| eps | -0.82 | -0.58 | -41.38 |
Revenue Growth: revenue increased to 4 million in 2024Q3 from 26 million in 2024Q2 representing a change of -85.42%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 60 million in 2024Q3 from 57 million in 2024Q2 representing a change of 5.42%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -60 million in 2024Q3 from -40 million in 2024Q2 representing a change of -50.69%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -72 million in 2024Q3 from -51 million in 2024Q2 representing a change of -41.63%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -62 million in 2024Q3 from -42 million in 2024Q2 representing a change of -48.56%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Gross Profit: Gross Profit decreased to 2 million in 2024Q3 from 24 million in 2024Q2 representing a change of -92.67%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 76 million in 2024Q3 from 75 million in 2024Q2 representing a change of 1.59%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.82 in 2024Q3 from -0.82 in 2024Q2 representing a change of -41.38%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001815442 | |||
| total assets | 575759000 | 603134000 | -4.54 |
| total liabilities | 180788000 | 112983000 | 60.01 |
| total equity | 394971000 | 490151000 | -19.42 |
| cash and cash equivalents | 109966000 | 68395000 | 60.78 |
| short term investments | 264915000 | 338771000 | -21.80 |
| long term investments | 61434000 | 152328000 | -59.67 |
| total current assets | 405317000 | 559494000 | -27.56 |
| total non current assets | 170442000 | 43640000 | 290.56 |
| total current liabilities | 85691000 | 63260000 | 35.46 |
| total non current liabilities | 95097000 | 49723000 | 91.25 |
| common stock | 6000 | 6000 | 0.00 |
| retained earnings | -530752000 | -383790000 | -38.29 |
| total debt | 84674000 | 17335000 | 388.46 |
Total Assets: Total Assets decreased to 576 million in 2023 from 603 million in 2022 representing a change of -4.54%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 181 million in 2023 from 113 million in 2022 representing a change of 60.01%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 395 million in 2023 from 490 million in 2022 representing a change of -19.42%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 265 million in 2023 from 339 million in 2022 representing a change of -21.8%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 405 million in 2023 from 559 million in 2022 representing a change of -27.56%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 86 million in 2023 from 63 million in 2022 representing a change of 35.46%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -531 million in 2023 from -384 million in 2022 representing a change of -38.29%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 85 million in 2023 from 17 million in 2022 representing a change of 388.46%. This indicates an increase in overall debt burden.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 110 million in 2023 from 68 million in 2022 representing a change of 60.78%. This indicates an increase in available liquid assets.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001815442 | |||
| total assets | 1034842000 | 826021000 | 25.28 |
| total liabilities | 141912000 | 141097000 | 0.58 |
| total equity | 892930000 | 684924000 | 30.37 |
| cash and cash equivalents | 110718000 | 67612000 | 63.75 |
| short term investments | 439252000 | 442341000 | -0.70 |
| long term investments | 366818000 | 198286000 | 84.99 |
| total current assets | 568715000 | 525407000 | 8.24 |
| total non current assets | 466127000 | 300613999 | 55.06 |
| total current liabilities | 66532000 | 62143000 | 7.06 |
| total non current liabilities | 75380000 | 78954000 | -4.53 |
| common stock | 7000 | 6000 | 16.67 |
| retained earnings | -683858000 | -621371000 | -10.06 |
| total debt | 88231000 | 88181000 | 0.06 |
Total Assets: Total Assets increased to 1,035 million in 2024Q3 from 826 million in 2024Q2 representing a change of 25.28%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 893 million in 2024Q3 from 685 million in 2024Q2 representing a change of 30.37%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 111 million in 2024Q3 from 68 million in 2024Q2 representing a change of 63.75%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 569 million in 2024Q3 from 525 million in 2024Q2 representing a change of 8.24%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 16.67%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 142 million in 2024Q3 from 141 million in 2024Q2 representing a change of 0.58%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 439 million in 2024Q3 from 442 million in 2024Q2 representing a change of -0.7%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 67 million in 2024Q3 from 62 million in 2024Q2 representing a change of 7.06%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -684 million in 2024Q3 from -621 million in 2024Q2 representing a change of -10.06%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 88 million in 2024Q3 from 88 million in 2024Q2 representing a change of 0.06%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001815442 | |||
| net change in cash | 41252000 | 20433000 | 101.89 |
| operating cash flow | -102826000 | -153085000 | 32.83 |
| free cash flow | -137306000 | -155921000 | 11.94 |
| capital expenditure | -34480000 | -2836000 | -1,115.80 |
| depreciation and amortization | 3565000 | 2977000 | 19.75 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 43118000 | 35480000 | 21.53 |
| accounts payables | 2038000 | 253000 | 705.53 |
| inventory | 23372000 | 2401000 | 873.43 |
| acquisitions net | 0 | -20519000 | 100.00 |
| investments in property plant and equipment | -34480000 | -2836000 | -1,115.80 |
| net cash used for investing activites | 139886000 | 20519000 | 581.74 |
| debt repayment | -76000 | -1130000 | 93.27 |
| common stock issued | 4268000 | 149825000 | -97.15 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 4192000 | 152999000 | -97.26 |
| cash at end of period | 115777000 | 74525000 | 55.35 |
| accounts receivables | -15000000 | -2401000 | -524.74 |
| cash at beginning of period | 74525000 | 54092000 | 37.77 |
Net Change in Cash: Net Change in Cash increased to 41 million in 2023 from 20 million in 2022 representing a change of 101.89%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -103 million in 2023 from -153 million in 2022 representing a change of 32.83%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -137 million in 2023 from -156 million in 2022 representing a change of 11.94%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -34 million in 2023 from -3 million in 2022 representing a change of -1115.8%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Receivables: Accounts Receivables decreased to -15 million in 2023 from -2 million in 2022 representing a change of -524.74%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Stock-Based Compensation: Stock-Based Compensation increased to 43 million in 2023 from 35 million in 2022 representing a change of 21.53%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 2 million in 2023 from 0 million in 2022 representing a change of 705.53%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001815442 | |||
| operating cash flow | -50190000 | -42936000 | -16.89 |
| free cash flow | -50001000 | -47625000 | -4.99 |
| capital expenditure | 189000 | -4689000 | 104.03 |
| depreciation and amortization | 1987000 | 1900000 | 4.58 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 14904000 | 14341000 | 3.93 |
| accounts receivables | 386000 | 327000 | 18.04 |
| accounts payables | 92000 | 31000 | 196.77 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 189000 | -4689000 | 104.03 |
| net cash used for investing activites | -157680000 | 15642000 | -1,108.06 |
| debt repayment | -641000 | -352000 | -82.10 |
| common stock issued | 251559000 | 1764000 | 14,160.71 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 250918000 | 1412000 | 17,670.40 |
| net change in cash | 48889000 | -25898000 | 288.78 |
| cash at end of period | 116501000 | 67612000 | 72.31 |
| cash at beginning of period | 67612000 | 93510000 | -27.70 |
Net Change in Cash: Net Change in Cash increased to 49 million in 2024Q3 from -26 million in 2024Q2 representing a change of 288.78%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -50 million in 2024Q3 from -43 million in 2024Q2 representing a change of -16.89%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -50 million in 2024Q3 from -48 million in 2024Q2 representing a change of -4.99%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from -5 million in 2024Q2 representing a change of 104.03%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 15 million in 2024Q3 from 14 million in 2024Q2 representing a change of 3.93%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 196.77%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q3 from 0 million in 2024Q2 representing a change of 18.04%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 1.35 | 0.87 | 55.09 |
| net income per share | -2.52 | -2.82 | 10.56 |
| operating cash flow per share | -1.76 | -2.84 | 37.93 |
| free cash flow per share | -2.35 | -2.89 | 18.63 |
| cash per share | 6.42 | 7.55 | -14.92 |
| book value per share | 6.77 | 9.09 | -25.54 |
| tangible book value per share | 6.77 | 9.09 | -25.54 |
| shareholders equity per share | 6.77 | 9.09 | -25.54 |
| interest debt per share | 1.45 | 0.32 | 347.86 |
| market cap | 1485985604.54 | 1346173395.84 | 10.39 |
| enterprise value | 1460693604.54 | 1295113395.84 | 12.78 |
| pe ratio | -10.11 | -8.87 | -14.04 |
| price to sales ratio | 18.91 | 28.75 | -34.23 |
| pocfratio | -14.45 | -8.79 | -64.34 |
| pfcf ratio | -10.82 | -8.63 | -25.35 |
| pb ratio | 3.76 | 2.75 | 36.99 |
| ptb ratio | 3.76 | 2.75 | 36.99 |
| ev to sales | 18.59 | 27.66 | -32.80 |
| enterprise value over ebitda | -10.2 | -8.54 | -19.44 |
| ev to operating cash flow | -14.21 | -8.46 | -67.91 |
| ev to free cash flow | -10.64 | -8.31 | -28.08 |
| earnings yield | -0.1 | -0.11 | 12.31 |
| free cash flow yield | -0.09 | -0.12 | 20.22 |
| debt to equity | 0.21 | 0.04 | 506.17 |
| debt to assets | 0.15 | 0.03 | 411.68 |
| net debt to ebitda | 0.18 | 0.34 | -47.54 |
| current ratio | 4.73 | 8.84 | -46.52 |
| interest coverage | -844.54 | -916.23 | 7.82 |
| income quality | 0.7 | 0.99 | -29.24 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.7 | 0.94 | -25.19 |
| research and ddevelopement to revenue | 2.41 | 3.51 | -31.41 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.34 | -0.02 | -1,710.05 |
| capex to revenue | 0.44 | 0.06 | 624.39 |
| capex to depreciation | 9.67 | 0.95 | 915.27 |
| stock based compensation to revenue | 0.55 | 0.76 | -27.59 |
| graham number | 19.58 | 23.99 | -18.39 |
| roic | -0.35 | -0.31 | -10.74 |
| return on tangible assets | -0.26 | -0.25 | -1.40 |
| graham net net | 3.57 | 5.38 | -33.66 |
| working capital | 319626000 | 496234000 | -35.59 |
| tangible asset value | 394971000 | 490151000 | -19.42 |
| net current asset value | 224529000 | 446511000 | -49.71 |
| invested capital | 420705000 | 509568000 | -17.44 |
| average receivables | 10649500 | 1336000 | 697.12 |
| average payables | 5705000 | 4170000 | 36.81 |
| average inventory | -6125000 | -10620000 | 42.33 |
| days sales outstanding | 87.14 | 19.78 | 340.62 |
| days payables outstanding | 13.66 | 531.5 | -97.43 |
| days of inventory on hand | 0 | -1501.93 | 100.00 |
| receivables turnover | 4.19 | 18.46 | -77.30 |
| payables turnover | 26.73 | 0.69 | 3,791.63 |
| inventory turnover | 0 | -0.24 | 100.00 |
| roe | -0.37 | -0.31 | -20.12 |
| capex per share | 0.59 | 0.05 | 1,023.47 |
ROE: Return on Equity (ROE) decreased to -0.37 on 2023-12-31 from -0.31 on 2022-12-31, representing a change of -20.12%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -10.11 on 2023-12-31 from -8.87 on 2022-12-31, representing a change of -14.04%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 4.73 on 2023-12-31 from 8.84 on 2022-12-31, representing a change of -46.52%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.21 on 2023-12-31 from 0.04 on 2022-12-31, representing a change of 506.17%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| KYMR | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.05 | 0.35 | -86.00 |
| net income per share | -0.82 | -0.58 | -42.57 |
| operating cash flow per share | -0.66 | -0.59 | -12.19 |
| free cash flow per share | -0.66 | -0.65 | -0.76 |
| cash per share | 7.22 | 6.98 | 3.50 |
| book value per share | 11.73 | 9.37 | 25.12 |
| tangible book value per share | 11.73 | 9.37 | 25.12 |
| shareholders equity per share | 11.73 | 9.37 | 25.12 |
| interest debt per share | 0.17 | 1.21 | -85.96 |
| market cap | 3603042396.75 | 2261188368.1 | 59.34 |
| enterprise value | 3580555396.75 | 2281757368.1 | 56.92 |
| pe ratio | -14.42 | -13.44 | -7.26 |
| price to sales ratio | 963.12 | 88.16 | 992.53 |
| pocfratio | -71.79 | -52.66 | -36.31 |
| pfcf ratio | -72.06 | -47.48 | -51.77 |
| pb ratio | 4.04 | 3.3 | 22.22 |
| ptb ratio | 4.04 | 3.3 | 22.22 |
| ev to sales | 957.11 | 88.96 | 975.92 |
| enterprise value over ebitda | -59.25 | -56.9 | -4.14 |
| ev to operating cash flow | -71.34 | -53.14 | -34.24 |
| ev to free cash flow | -71.61 | -47.91 | -49.46 |
| earnings yield | -0.02 | -0.02 | 6.77 |
| free cash flow yield | -0.01 | -0.02 | 34.11 |
| debt to equity | 0.01 | 0.13 | -88.82 |
| debt to assets | 0.01 | 0.11 | -88.37 |
| net debt to ebitda | 0.37 | -0.51 | 172.55 |
| current ratio | 8.55 | 8.45 | 1.10 |
| interest coverage | -1202.07 | -834.84 | -43.99 |
| income quality | 0.8 | 1.02 | -21.31 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 4.13 | 0.68 | 509.95 |
| research and ddevelopement to revenue | 16.15 | 2.23 | 622.83 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.11 | 96.55 |
| capex to revenue | 0.05 | 0.18 | -72.36 |
| capex to depreciation | 0.1 | 2.47 | -96.15 |
| stock based compensation to revenue | 3.98 | 0.56 | 612.56 |
| graham number | 14.72 | 11.02 | 33.56 |
| roic | -0.08 | -0.07 | -20.88 |
| return on tangible assets | -0.06 | -0.05 | -18.58 |
| graham net net | 5.37 | 5.07 | 6.06 |
| working capital | 502183000 | 463264000 | 8.40 |
| tangible asset value | 892930000 | 684924000 | 30.37 |
| net current asset value | 426803000 | 384310000 | 11.06 |
| invested capital | 601492000 | 563703000 | 6.70 |
| average receivables | 1510500 | 1866999.5 | -19.09 |
| average payables | 6502000 | 6661000 | -2.39 |
| average inventory | 0 | 0.5 | -100.00 |
| days sales outstanding | 31.68 | 5.98 | 429.93 |
| days payables outstanding | 292.23 | 308.37 | -5.23 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 2.84 | 15.05 | -81.13 |
| payables turnover | 0.31 | 0.29 | 5.52 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.07 | -0.06 | -13.95 |
| capex per share | 0.0 | 0.06 | -96.13 |
ROE: Return on Equity (ROE) decreased to -0.07 on 2024-09-30 Q3 from -0.06 on 2024-06-30 Q2, representing a change of -13.95%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -14.42 on 2024-09-30 Q3 from -13.44 on 2024-06-30 Q2, representing a change of -7.26%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 8.55 on 2024-09-30 Q3 from 8.45 on 2024-06-30 Q2, representing a change of 1.10%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.01 on 2024-09-30 Q3 from 0.13 on 2024-06-30 Q2, representing a change of -88.82%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -29.05 which is lower than current price 45.95, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-11-05 07:00:00
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
Sentiment: Positive
Publish Date: 2024-11-03 16:11:28
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - CFO Conference Call Participants Marc Frahm - TD Cowen Kalpit Patel - B. Riley Alexei Siniakov - Truist Securities Brad Canino - Stifel Nicolaus Gospel Enyindah-Asonye - Morgan Stanley Kelly Shi - Jefferies Jeff Jones - Oppenheimer Eric Joseph - J.P.
Sentiment: Negative
Publish Date: 2024-11-01 11:20:33
Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.
Sentiment: Negative
Publish Date: 2024-10-31 09:40:29
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago.
Sentiment: Positive
Publish Date: 2024-10-31 07:30:00
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025
Sentiment: Positive
Publish Date: 2024-10-24 11:05:34
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sentiment: Negative
Publish Date: 2024-10-24 07:00:00
KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases
Sentiment: Negative
Publish Date: 2024-10-23 07:15:00
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET.
Sentiment: Negative
Publish Date: 2024-10-23 07:00:00
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data from its innovative TPD platform will be presented across three poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The presentations include new data on its preclinical biomarker-based approach for KT-253, its MDM2 degrader.
Sentiment: Negative
Publish Date: 2024-10-10 10:33:18
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.
Sentiment: Negative
Publish Date: 2024-10-09 07:00:00
KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases
Sentiment: Positive
Publish Date: 2024-10-06 14:58:27
Kymera Therapeutics' innovative TPD technology degrades disease-causing proteins, with promising candidates like KT-474 and KT-621 targeting large TAMs in immunology and oncology. The company's approach leverages the body's proteasome system to degrade harmful proteins. This could lead to safer and less invasive treatments. Kymera's cash runway of approximately 4.9 years is expected to support the advancement of its pipeline until 2027.
Sentiment: Negative
Publish Date: 2024-09-25 07:00:00
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease
Sentiment: Neutral
Publish Date: 2024-09-06 12:37:54
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
Sentiment: Negative
Publish Date: 2024-08-28 07:00:00
WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events:
Sentiment: Positive
Publish Date: 2024-08-21 11:15:00
WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 2,830,533 shares of its common stock, which includes 828,220 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,519,159 shares of its common stock in the offering. The shares of common stock were sold at a public offering price of $40.75 per share and the pre-funded warrants were sold at a public offering price of $40.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Kymera from the offering were approximately $258.75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera.
Sentiment: Positive
Publish Date: 2024-08-20 14:05:46
Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.
Sentiment: Positive
Publish Date: 2024-08-19 22:45:00
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,519,159 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $40.75 per share and the pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 828,220 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters' option to purchase additional shares. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on August 21, 2024, subject to the satisfaction of customary closing conditions.
Sentiment: Positive
Publish Date: 2024-08-19 16:01:00
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
